Personalized Evidence-based Treatment in Patients With Invasive Breast Cancer

NCT ID: NCT04798976

Last Updated: 2021-03-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-01

Study Completion Date

2021-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A population-based case-cohort study of breast cancer-specific survival among all first invasive breast cancer cases

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer-specific Survival

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CDSS (MedicBK) Analysis

neoadjuvant/adjuvant therapy

Intervention Type DRUG

chemotherapy/endocrine therapy/surgery/radiotherapy

Core Laboratory Analysis

neoadjuvant/adjuvant therapy

Intervention Type DRUG

chemotherapy/endocrine therapy/surgery/radiotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

neoadjuvant/adjuvant therapy

chemotherapy/endocrine therapy/surgery/radiotherapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All women with stage I-III disease who survived at least 12 months post-diagnosis

Exclusion Criteria

Unknown cause of death Treatment outside the region (thus precluding the treatment assessment)
Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Center for New Medical Technologies, Novosibirsk, Russia

OTHER

Sponsor Role collaborator

I.M. Sechenov First Moscow State Medical University

OTHER

Sponsor Role collaborator

Center of Personalized Medicine, Pirogova

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Evgeny Pokushalov

Director for research and development

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Evgeny Pokushalov

Novosibirsk, , Russia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Russia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Evgeny Pokushalov, Prof. MD PhD

Role: CONTACT

89139254858

Irina Ostanina, MD

Role: CONTACT

+79039031563

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Evgeny Pokushalov, Prof. MD PhD

Role: primary

89139254858

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20210312

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.